Yazılar

Eli Lilly Unveils AI-Powered TuneLab to Speed Drug Discovery

/in /tarafından

Eli Lilly (LLY.N) announced on Tuesday the launch of TuneLab, an artificial intelligence and machine learning platform designed to give biotech companies access to advanced drug discovery models trained on decades of Lilly’s research data.

The platform represents more than $1 billion in proprietary data investments and aims to level the playing field by letting smaller biotech firms access the same AI-driven tools Lilly scientists use internally.

“Lilly TuneLab was created to be an equalizer so that smaller companies can access some of the same AI capabilities used every day by Lilly scientists,” said Daniel Skovronsky, Lilly’s chief scientific officer.

Two biotech firms — Circle Pharma and insitro — are already early partners. Circle will apply TuneLab’s tools to cancer drug development, while insitro will contribute new AI models for small molecule discovery, enhancing TuneLab’s capabilities.

The move reflects a broader industry shift toward AI in research and development. Analysts at Jefferies forecast that AI-related R&D spend could reach $30–40 billion by 2040, as drugmakers adopt AI for discovery, testing, and reducing reliance on animal studies, in line with FDA goals.

TuneLab operates on datasets covering hundreds of thousands of unique molecules. In exchange for access, biotech partners provide their own training data, further strengthening the platform’s predictive power and long-term value.

Rising Pancreatic Cancer Cases in Under-50 Adults Highlight Low Awareness Levels

/in /tarafından

A recent survey conducted by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James) has revealed a troubling gap in awareness about pancreatic cancer among adults under 50. Despite a rising number of pancreatic cancer diagnoses in younger individuals, the survey found that more than half of the respondents failed to recognize the early warning signs of the disease. Furthermore, about one-third mistakenly believed that pancreatic cancer only affected older adults. This lack of awareness extends to preventive measures as well, with many unaware of how lifestyle changes could reduce the risk of developing this deadly cancer.

Rising Diagnoses in People Under 50 Spark Concerns

The increase in pancreatic cancer diagnoses among younger individuals has raised alarms among health experts. Dr. Zobeida Cruz-Monserrate, co-leader of the Molecular Carcinogenesis and Chemoprevention Programme at OSUCCC—James, pointed out that pancreatic cancer rates in people under 50 have been climbing by about 1% annually. This shift in the age demographics of the disease is both unusual and concerning, as pancreatic cancer is notorious for being diagnosed at advanced stages, when treatment options are far less effective. The lack of early detection methods contributes to the grim prognosis associated with the disease.

Factors Influencing Pancreatic Cancer Risk

Genetics account for approximately 10% of pancreatic cancer cases, but lifestyle choices play a much larger role in determining an individual’s risk. According to the American Cancer Society, factors such as obesity significantly increase one’s lifetime risk of pancreatic cancer, with obesity linked to a 20% increase in risk. Dr. Cruz-Monserrate stressed that maintaining a healthy weight, staying physically active, and moderating alcohol consumption are key lifestyle adjustments that can not only lower the risk of pancreatic cancer but also improve overall health. These preventive measures offer a practical approach to combating the rising threat of the disease.

The findings from this survey underscore the urgent need for increased awareness and education on pancreatic cancer, particularly among younger adults. Public health initiatives must focus on the importance of recognizing symptoms early and promoting healthy lifestyle choices. With more attention on prevention and early detection, the burden of pancreatic cancer could be reduced, potentially saving lives in future generations.

Nobel Prize in Medicine Awarded to American Biologists for Discovery of microRNA

/in /tarafından

The 2024 Nobel Prize in physiology or medicine has been awarded to American scientists Victor Ambros and Gary Ruvkun for their groundbreaking work on the discovery of microRNA, a molecule that plays a crucial role in regulating how cells function. This discovery is being hailed as a fundamental breakthrough in understanding gene regulation.

Ambros, a professor at the University of Massachusetts Medical School, and Ruvkun, a professor of genetics at Harvard Medical School, spent decades researching gene regulation. Their work revealed how microRNAs help control the production of proteins in cells, which is essential for the development of various cell types, including muscle and nerve cells, despite all cells containing the same genetic material. The Nobel committee praised their research as uncovering “an entirely new dimension to gene regulation.”

The discovery of microRNA, which dates back to the early 1990s, was initially met with skepticism. It was first observed in the tiny roundworm C. elegans, leading many scientists to dismiss it as a peculiarity. However, Ruvkun later discovered that microRNAs are present throughout the animal kingdom, sparking widespread interest in the field. Today, tens of thousands of microRNAs have been identified in various organisms.

The significance of microRNAs extends beyond basic biology; they have been linked to numerous human diseases, including cancer. MicroRNAs can malfunction, leading to conditions like cancer, hearing loss, and skeletal disorders. Research is ongoing to develop therapies that target microRNAs to treat these conditions, although there are still technical hurdles to overcome before such treatments are available.

The Nobel committee acknowledged that while the discovery of microRNA may not have immediate clinical applications, its long-term impact on medicine and biology is undeniable. Experts have noted the potential of microRNAs in diagnostic and therapeutic strategies, particularly in the field of cancer research.

Victor Ambros and Gary Ruvkun’s discovery has reshaped how scientists understand gene regulation, highlighting the complexity of cellular processes and how they contribute to the development and evolution of organisms. Their Nobel Prize recognition follows years of anticipation, as their work has opened new avenues in the study of genetics and cell biology.